CRISPR Technology, Gene Therapies, and Intellectual Property Law

Entrance

One of the most groundbreaking developments offered by modern biotechnology is CRISPR-Cas9 gene editing technology. This technology precise, rapid, and cost-effective changes, creating significant potential, particularly rare genetic diseases, cancer treatments , and agricultural biotechnology .

However, the commercialization and clinical use of CRISPR technology has brought with it patent disputes , limitations on intellectual property rights , and ethical and moral debates . This paper will evaluate the patentability of CRISPR technology , the legal nature of gene therapies , ethical boundaries , and the balance between public interest and private enterprise .

1. Definition and Application Areas of CRISPR Technology

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is derived from a natural immune mechanism that bacteria develop against viral infections. When used in conjunction with the Cas9 enzyme, it can target, cut, and rearrange genetic material.

Areas of application:

• Human gene therapies (e.g., sickle cell anemia, beta thalassemia),

• Cancer immunotherapies,

• Agricultural biotechnology (creating more resistant plant species),

• Genetic experiments in animal models.

2. CRISPR and Patent Law: Initial Conflicts

One of the most notable legal developments accompanying the development of CRISPR technology has been the patent war between the Broad Institute (MIT-Harvard) and the University of California (Berkeley) . This conflict has led to serious debates about who first developed CRISPR technology , which application areas it is specific to , and which technical details are patentable

Patentable Elements:

• Specific variants of the CRISPR system that have been made applicable in a laboratory setting,

• Cas9 has specific genome targeting methods,

• CRISPR tools used in therapeutic applications.

Non-patentable Elements:

• Natural genetic sequences,

• Enzymes and proteins that exist in nature,

• Natural biological mechanisms that are of a discovery nature (unless they are direct inventions).

3. Patent Protection from the Perspective of Turkish Law and International Legislation

In Turkey, biotechnological inventions such as CRISPR technology the Industrial Property Law No. 6769. Accordingly:

Article 82/2-b of the Industrial Property Law states: "Diagnostic and therapeutic methods to be applied to the human and animal body cannot be patented." However, this article covers the methods themselves ; the tools , compounds , or genetic vectors used in these methods may be subject to patent protection if they are novel, involve an inventive step, and meet the condition of industrial applicability .

At the international level:

• The TRIPS Agreement (Article 27) recognizes patent protection without distinction between technological fields, but includes flexibilities relating to public health.

• The European Patent Convention (EPC)imposes limitations, particularly on the patenting of human genes (e.g., EPC Article 53/a: “Inventions contrary to public order and morals cannot be patented.”).

4. Gene Therapies and Legal-Ethical Boundaries

Gene therapies using CRISPR technology raise serious ethical debates, especially when it comes to making hereditary changes in human embryos or germ cells.

Ethical Boundaries and Legal Regulations:

• Oviedo Convention Article 13: Genetic modification may only be carried out for therapeutic purposes; it may not be done for the purpose of species improvement or achieving aesthetic/genetic superiority.

• The Istanbul Protocol and National Clinical Trials Legislationrequire explicit consent, ethical committee approval, and scientific necessity for human trials.

• Law (KVKK) , genetic data is considered "special categories of personal data"; its processing is subject to strict rules.

5. Balancing Public Interest and Private Rights: Compulsory Licensing and Exceptions

Patent protection for CRISPR-based drugs or therapeutic devices may occasionally conflict with public health . In such cases, legal systems may limit private property rights through mechanisms such as compulsory licensing , research exceptions , or use in the public interest

• Articles 129-132 of theIndustrial Property Law: Compulsory licensing of patents may be granted when there is a public interest.

• Research exception: Academic or clinical research does not infringe patent rights unless it is for commercial purposes.

• Public data sharing: Biomedical ethics encourage data sharing in CRISPR studies, with certain limitations.

Conclusion

CRISPR technology has the potential to revolutionize a wide range of fields, from treating genetic diseases to agricultural production. However, the process of turning this potential into commercial gain must be carefully managed within the framework of the delicate balance of intellectual property law , ethical limitations , and public health concerns

The patent system encourages innovation:

• We should not restrict the free flow of genetic information,

• We must not obstruct access to treatment

• Threats to public health should be limited.

Therefore, the legal assessment of biotechnological innovations such as CRISPR should not be limited solely to the industrial property regime; it should also be considered in conjunction with bioethics , human rights , data protection law , and public policies